ClinicalTrials.gg
Sign In
CompletedNCT00642785Updated Jun 3, 2008

Activation of Alternative Cellular Energy (ACE) Pathway in the Therapy of Herpes Virus Infections

An observational study in Herpes Simplex and Herpes Zoster, sponsored by Institute of Progressive Medicine. Completed. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-06-03.

Sponsored by Institute of Progressive Medicine · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The research question to be addressed is whether indirect phototherapy based activation of the body's alternative cellular energy (ACE) pathway will lead to expedited healing of active herpes simplex virus (HSV) and herpes zoster virus (HZV)skin lesions, and also possibly inhibit both latent HSV infections and residual HZV infections.

02

Conditions studied

  • Herpes Simplex
  • Herpes Zoster

Keywords

  • herpes
  • HSV
  • zoster
  • HZV
  • shingles
03

In context

Herpes Simplex

302 studies on the registry are indexed under Herpes Simplex; 30 are open to participants now.

This study's planned enrollment of 500 is above the median of 190 across 56 observational studies indexed under Herpes Simplex.

Browse Herpes Simplex studies →

Lead sponsor

Institute of Progressive Medicine is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

HSV and HZV infected patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of active, latent or residual HSV or HZV infection

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to provide Informed Consent
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
500 participants (estimated)

Groups and cohorts

  • 1

    Patients with active oral or genital HSV skin lesions

  • 2

    Patients with a history of recurrent oral or genital HSV but without an active lesion at the time of treatment

  • 3

    Patients with active shingles/zoster

  • 4

    Patients with post herpetic neuralgia

06

What researchers measure

Primary outcomes

  1. Expedited healing of active lesions

    Time frame: Within 1 day following therapy

Secondary outcomes

  1. Recurrence of lesions and/or symptoms

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Martin WJ, Stoneburner J. Symptomatic relief of herpetic skin lesions utilizing an energy-based approach to healing. Exp Mol Pathol. 2005 Apr;78(2):131-4. doi: 10.1016/j.yexmp.2004.10.007. Epub 2005 Jan 5. PubMed 15713438 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2008
First posted
Mar 25, 2008
Start
Jan 2008
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Last update
Jun 3, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00642785
Lead sponsor
Institute of Progressive Medicine
First posted
Mar 25, 2008
Start date
Jan 2008
Primary completion
Apr 2008
Completion
Apr 2008
Last update
Jun 3, 2008

Study contacts

W John Martin, MD, PhD
principal investigator · Institute of Progressive Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Herpes Simplex →

Other studies from this sponsor

Institute of Progressive Medicine

Start the discussion